NCT01463982 - Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

December 31, 2013

Conditions

Solid TumorAdvanced Cancer

Interventions

DRUG

Oratecan and Capecitabine

"Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14"

Trial Locations (1)

Unknown

Hanmi Pharmaceuticals, Co., Ltd, Seoul